2012
‘Identification of peptidoglycan in peritoneal dialysis solution as root cause of aseptic peritonitis’
PDA Annual Pharmaceutical Microbiology Meeting, Rockville, MD
2007
Medical College of Wisconsin, Department of Nephrology
‘Glucotoxicity in Peritoneal Dialysis’
‘Biocompatibility in PD –Is it important?’
2005
Harvard Business School 2005 Annual Healthcare Conference
Medical Devices Panel Committee
2005
Plenary Session: 33rd Renal Society of Australia, Hobart, Tasmania
‘PD – Why should patients choose this treatment option?’
‘Workshops: PD solution development’
2005
Grand Rounds Sunnybrook & Women’s College Health Sciences Centre, Toronto, Canada
‘New PD Solutions: Demonstrated Clinical Benefit and Emerging Evidence’
2005
Grand Rounds London Health Sciences Centre – Victoria Campus, London, Ontario, Canada
New PD Solutions: Demonstrated Clinical Benefit and Emerging Evidence’
2004
24th Annual Conference on Peritoneal Dialysis, San Antonio, TX
‘Advantages of products with reduced glucose degradation products and/or advanced Glycosylation end products. What is the evidence?’
2003
Reunion Société de Néphrologie et Société Franocophone de Dialyse, Nancy, France
‘Xenotransplantation, tissue engineering and stem cell therapy for acute and chronic renal failure. What can we hope for?’
2002
12th Annual Western PD Conference, Saskatoon, Saskachewan
‘Pre-clinical and clinical performance of Physioneal’
2002
22nd Annual Conference on Peritoneal Dialysis, Tampa, Florida
‘Update on worldwide peritonitis rates – Are they better or worse’
‘Peritonitis and host defense systems’
2001
XXXVIII ERA-EDTA Congress, Vienna, Austria
‘New Biocompatible PD solutions: the future is now’
2000
10th Annual Western PD Conference, Edmonton, Alberta, Canada
‘Biocompatibility of PD Solutions’
2000
Festschrift symposium for Lee Henderson. Panel Discussion: ASN, Toronto, Canada
2000
12th Anniversary PD Seminar, Seoul, Korea
‘Biocompatibility of new PD solutions: Relevance of pre-clinical studies’
2000
Seventh International Course on Peritoneal Dialysis, Vicenza, Italy
‘How to prevent glucose toxicity of PD solutions’
1999
Huddinge Hospital, Stockholm, Sweden
‘The biocompatibility of bicarbonate/lactate PD solutions’
1999
19th Annual Conference on Peritoneal Dialysis, North Carolina
‘Vancomycin resistance in dialysis patients’
1999
19th Annual Conference on Peritoneal Dialysis, North Carolina
‘Enhancing intraperitoneal host defenses – will it be clinically practical?
1998
The VIIth New Zealand Nephrologists & Transplant Surgeons Meeting, Queenstown, New Zealand
PD Solution Biocompatibility
1997
Gambro Healthcare 1997 Medical Directors’ Meeting, Scottsdale, AZ
‘Peritoneal Catheter Infection Management’
1997
XV National Mexican Congress of Nephrology, Mexico City
‘Peritoneal Host Defense Mechanisms’
1997
XV National Mexican Congress of Nephrology, Mexico City
‘PD Catheter Biomaterials for Today and Tomorrow’
1996
Ad Hoc Advisory Committee on Peritonitis Management, Seattle, WA
‘Biofilm and its role in peritonitis: Are these effective therapies?’
1995
Sixth Annual Western Canadian PD Conference, University of Alberta Hospitals, Edmonton, Canada
‘Exit site infections in PD: Pathogenesis, Prevention and Treatment’
1995
IV Panamerican Society for Dialysis and Transplantation, Mexico City
‘Disconnect systems and peritonitis rates’
1995
IV Panamerican Society for Dialysis and Transplantation, Mexico City
‘Biocompatibility with cellulosic membranes’
1995
International Society of Peritoneal Dialysis, Stockholm, Sweden
State of the Art Lecture: ‘Host Defense in Peritoneal Dialysis’
1994
International Symposium on Adequacy of Peritoneal Dialysis, Berlin
‘Host defense in peritoneal dialysis’: cellular and humoral aspects’
1993
Société d’Etudes de Promotion en Immuno-Allergologie, Pasteur Institute
‘Allergic reactions in hemodialysis’
1993
Lister Rounds Lecture Series, The Toronto Hospital, Toronto, Ontario
‘Bacteriology and immunology of CAPD-associated peritonitis’
1992
Vith Congress of the International Society for Peritoneal Dialysis, Thessaloniki, Greece
‘Peritoneal immune defenses in CAPD: clinical relevance and practical implications’
1992
National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD
‘Biocompatibility of hemodialysis membranes’
1992
Musculoskeletal Research Institute, Herndon, VA
‘Peritoneal dialysis and biomaterial-centered infection’
1992
Monterey Community Dialysis Convention, Yosemite National Park, CA
‘Mechanisms and biological consequences of hemodialysis membrane bioincompatibility’
1990
36th Annual meeting of American Society for Artificial Internal Organs, Washington D.C.
‘Dialysate endotoxin permeation of membranes’
1990
26th Workshop for Dialysis Physicians, Prien am Chiemsee, W. Germany
‘Dialysis-associated peritonitis: Causes and interventions’
1989
KRUF Institute of Renal Disease Research, U. of Cardiff, at Royal College of Physicians, London, U.K.
‘Biofilm and catheters in CAPD’
1989
American Nephrology Nurses Association, Syracuse, NY
‘Future trends in dialysis’
1988
8th Annual CAPD Conference, Kansas City, MO
‘Update on biofilm in CAPD’
1987
National Kidney Foundation, Chicago, IL
‘Clinical improvements for dialysis complications’
1985
Department of Urology, Northwestern Medical School, Chicago, IL
‘Bacterial colonization of medical devices’
1981
Pharmaceutical Society of Great Britain, London, England
‘Theory and practice of freeze-thaw methods for antibiotics’
HankinsonHolmes 